Archives of Osteoporosis

, 13:29 | Cite as

Bone: best papers of the year 2017

  • Michaël R. LaurentEmail author



An overview of selected papers related to bone published in 2017 is provided.


This paper accompanies a lecture at the 2018 Belgian Bone Club annual Clinical Update Symposium held in Brussels on January 20th, discussing the best papers (in the opinion of the author) published in the previous year.


A PubMed search using the keyword “bone” and articles published in 2017.


Hot topics include screening for osteoporosis, novel anabolic drugs such as romosozumab and abaloparatide for osteoporosis and rare metabolic bone diseases, as well as long-term efficacy of denosumab and possible risk of multiple vertebral fractures following its discontinuation. Other selected articles cover effectiveness of bisphosphonates and changes in mineralization after long-term use, new guidelines for glucocorticoid- and aromatase inhibitor-induced osteoporosis, increasing use of high-dose vitamin D supplements despite lack of evidence for their widespread high-dose use, and cardiovascular safety concerns surrounding the use of calcium supplements. Other topics discussed are effects of diabetes on bone health, reciprocal crosstalk between bone cells and adipose tissue, and resistance exercise training to prevent bone loss and sarcopenia.


These papers offer a hopeful outlook for a better treatment and management of patients with osteoporosis and other metabolic bone diseases anno 2018.


Osteoporosis Screening Bone anabolic drugs Vertebral fractures Vitamin D Calcium supplements 


Funding information

No funding was obtained related to this work.

Compliance with ethical standards

Conflicts of interest

MRL is a member of the Board of the Belgian Bone Club and has received consultancy fees from Alexion, Novartis, and Sandoz and lecture fees from Amgen. The opinions in this work represent the sole view of the author and not of the Belgian Bone Club.


  1. 1.
    Shepstone L, Lenaghan E, Cooper C, Clarke S, Fong-Soe-Khioe R, Fordham R et al (2017) Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial. Lancet 391:741–747. CrossRefPubMedGoogle Scholar
  2. 2.
    Compston J, Cooper A, Cooper C, Gittoes N, Gregson C, Harvey N et al (2017) UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos 12(1):43CrossRefGoogle Scholar
  3. 3.
    Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377(15):1417–1427CrossRefGoogle Scholar
  4. 4.
    Langdahl BL, Libanati C, Crittenden DB, Bolognese MA, Brown JP, Daizadeh NS, Dokoupilova E, Engelke K, Finkelstein JS, Genant HK, Goemaere S, Hyldstrup L, Jodar-Gimeno E, Keaveny TM, Kendler D, Lakatos P, Maddox J, Malouf J, Massari FE, Molina JF, Ulla MR, Grauer A (2017) Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet 390(10102):1585–1594CrossRefGoogle Scholar
  5. 5.
    Cosman F, Miller PD, Williams GC, Hattersley G, Hu MY, Valter I, Fitzpatrick LA, Riis BJ, Christiansen C, Bilezikian JP, Black D (2017) Eighteen months of treatment with subcutaneous abaloparatide followed by 6 months of treatment with alendronate in postmenopausal women with osteoporosis: Results of the ACTIVExtend Trial. Mayo Clin Proc 92(2):200–210CrossRefGoogle Scholar
  6. 6.
    Glorieux FH, Devogelaer JP, Durigova M, Goemaere S, Hemsley S, Jakob F, Junker U, Ruckle J, Seefried L, Winkle PJ (2017) BPS804 anti-sclerostin antibody in adults with moderate osteogenesis imperfecta: results of a randomized phase 2a trial. J Bone Miner Res 32(7):1496–1504CrossRefGoogle Scholar
  7. 7.
    Seefried L, Baumann J, Hemsley S, Hofmann C, Kunstmann E, Kiese B, Huang Y, Chivers S, Valentin MA, Borah B, Roubenoff R, Junker U, Jakob F (2017) Efficacy of anti-sclerostin monoclonal antibody BPS804 in adult patients with hypophosphatasia. J Clin Invest 127(6):2148–2158CrossRefGoogle Scholar
  8. 8.
    Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, Czerwiński E, Fahrleitner-Pammer A, Kendler DL, Lippuner K, Reginster JY, Roux C, Malouf J, Bradley MN, Daizadeh NS, Wang A, Dakin P, Pannacciulli N, Dempster DW, Papapoulos S (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 5(7):513–523CrossRefGoogle Scholar
  9. 9.
    Cummings SR, Ferrari S, Eastell R, Gilchrist N, Jensen JB, McClung M et al (2017) Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J Bone Miner Res 33:190–198. CrossRefPubMedGoogle Scholar
  10. 10.
    Anastasilakis AD, Polyzos SA, Makras P, Aubry-Rozier B, Kaouri S, Lamy O (2017) Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases. J Bone Miner Res 32(6):1291–1296CrossRefGoogle Scholar
  11. 11.
    Axelsson KF, Nilsson AG, Wedel H, Lundh D, Lorentzon M (2017) Association between alendronate use and hip fracture risk in older patients using oral prednisolone. JAMA 318(2):146–155CrossRefGoogle Scholar
  12. 12.
    Axelsson KF, Wallander M, Johansson H, Lundh D, Lorentzon M (2017) Hip fracture risk and safety with alendronate treatment in the oldest-old. J Intern Med 282(6):546–559CrossRefGoogle Scholar
  13. 13.
    Lloyd AA, Gludovatz B, Riedel C, Luengo EA, Saiyed R, Marty E, Lorich DG, Lane JM, Ritchie RO, Busse B, Donnelly E (2017) Atypical fracture with long-term bisphosphonate therapy is associated with altered cortical composition and reduced fracture resistance. Proc Natl Acad Sci U S A 114(33):8722–8727CrossRefGoogle Scholar
  14. 14.
    Shah FA, Lee BEJ, Tedesco J, Larsson Wexell C, Persson C, Thomsen P, Grandfield K, Palmquist A (2017) Micrometer-sized magnesium whitlockite crystals in micropetrosis of bisphosphonate-exposed human alveolar bone. Nano Lett 17(10):6210–6216CrossRefGoogle Scholar
  15. 15.
    Roca-Ayats N, Balcells S, Garcia-Giralt N, Falco-Mascaro M, Martinez-Gil N, Abril JF et al (2017) GGPS1 mutation and atypical femoral fractures with bisphosphonates. N Engl J Med 376(18):1794–1795CrossRefGoogle Scholar
  16. 16.
    Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE et al (2017) American College of Rheumatology Guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheumatol 69(8):1521–1537CrossRefGoogle Scholar
  17. 17.
    Hadji P, Aapro MS, Body JJ, Gnant M, Brandi ML, Reginster JY, Zillikens MC, Glüer CC, de Villiers T, Baber R, Roodman GD, Cooper C, Langdahl B, Palacios S, Kanis J, al-Daghri N, Nogues X, Eriksen EF, Kurth A, Rizzoli R, Coleman RE (2017) Management of aromatase inhibitor-associated bone loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG. J Bone Oncol 7:1–12CrossRefGoogle Scholar
  18. 18.
    Himelstein AL, Foster JC, Khatcheressian JL, Roberts JD, Seisler DK, Novotny PJ, Qin R, Go RS, Grubbs SS, O’Connor T, Velasco MR Jr, Weckstein D, O’Mara A, Loprinzi CL, Shapiro CL (2017) Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial. JAMA 317(1):48–58CrossRefGoogle Scholar
  19. 19.
    Wilson LM, Rebholz CM, Jirru E, Liu MC, Zhang A, Gayleard J, Chu Y, Robinson KA (2017) Benefits and harms of osteoporosis medications in patients with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 166(9):649–658CrossRefGoogle Scholar
  20. 20.
    Vogel KA, Martin BR, McCabe LD, Peacock M, Warden SJ, McCabe GP et al (2017) The effect of dairy intake on bone mass and body composition in early pubertal girls and boys: a randomized controlled trial. Am J Clin Nutr 105(5):1214–1229CrossRefGoogle Scholar
  21. 21.
    Lappe J, Watson P, Travers-Gustafson D, Recker R, Garland C, Gorham E, Baggerly K, McDonnell SL (2017) Effect of vitamin D and calcium supplementation on cancer incidence in older women: a randomized clinical trial. JAMA 317(12):1234–1243CrossRefGoogle Scholar
  22. 22.
    Mousa A, Naderpoor N, de Courten MP, Teede H, Kellow N, Walker K, Scragg R, de Courten B (2017) Vitamin D supplementation has no effect on insulin sensitivity or secretion in vitamin D-deficient, overweight or obese adults: a randomized placebo-controlled trial. Am J Clin Nutr 105(6):1372–1381PubMedGoogle Scholar
  23. 23.
    Scragg R, Stewart AW, Waayer D, Lawes CMM, Toop L, Sluyter J, Murphy J, Khaw KT, Camargo CA Jr (2017) Effect of monthly high-dose vitamin D supplementation on cardiovascular disease in the vitamin D assessment study : A Randomized Clinical Trial. JAMA Cardiol 2(6):608–616CrossRefGoogle Scholar
  24. 24.
    Zittermann A, Ernst JB, Prokop S, Fuchs U, Dreier J, Kuhn J, Knabbe C, Birschmann I, Schulz U, Berthold HK, Pilz S, Gouni-Berthold I, Gummert JF, Dittrich M, Börgermann J (2017) Effect of vitamin D on all-cause mortality in heart failure (EVITA): a 3-year randomized clinical trial with 4000 IU vitamin D daily. Eur Heart J 38(29):2279–2286CrossRefGoogle Scholar
  25. 25.
    Aglipay M, Birken CS, Parkin PC, Loeb MB, Thorpe K, Chen Y, Laupacis A, Mamdani M, Macarthur C, Hoch JS, Mazzulli T, Maguire JL, TARGet Kids! Collaboration (2017) Effect of high-dose vs standard-dose wintertime vitamin D supplementation on viral upper respiratory tract infections in young healthy children. JAMA 318(3):245–254CrossRefGoogle Scholar
  26. 26.
    Ginde AA, Blatchford P, Breese K, Zarrabi L, Linnebur SA, Wallace JI, Schwartz RS (2017) High-dose monthly vitamin D for prevention of acute respiratory infection in older long-term care residents: a randomized clinical trial. J Am Geriatr Soc 65(3):496–503CrossRefGoogle Scholar
  27. 27.
    Rooney MR, Harnack L, Michos ED, Ogilvie RP, Sempos CT, Lutsey PL (2017) Trends in use of high-dose vitamin D supplements exceeding 1000 or 4000 international units daily, 1999-2014. JAMA 317(23):2448–2450CrossRefGoogle Scholar
  28. 28.
    Rahme M, Sharara SL, Baddoura R, Habib RH, Halaby G, Arabi A, Singh RJ, Kassem M, Mahfoud Z, Hoteit M, Daher RT, Bassil D, el Ferkh K, el-Hajj Fuleihan G (2017) Impact of calcium and two doses of vitamin D on bone metabolism in the elderly: a randomized controlled trial. J Bone Miner Res 32(7):1486–1495CrossRefGoogle Scholar
  29. 29.
    Laurent MR, Gielen E, Pauwels S, Vanderschueren D, Bouillon R (2017) Hypervitaminosis D associated with tanning bed use: a case report. Ann Intern Med 166(2):155–156CrossRefGoogle Scholar
  30. 30.
    Larsson SC, Burgess S, Michaelsson K (2017) Association of genetic variants related to serum calcium levels with coronary artery disease and myocardial infarction. JAMA 318(4):371–380CrossRefGoogle Scholar
  31. 31.
    Snyder PJ, Kopperdahl DL, Stephens-Shields AJ, Ellenberg SS, Cauley JA, Ensrud KE, Lewis CE, Barrett-Connor E, Schwartz AV, Lee DC, Bhasin S, Cunningham GR, Gill TM, Matsumoto AM, Swerdloff RS, Basaria S, Diem SJ, Wang C, Hou X, Cifelli D, Dougar D, Zeldow B, Bauer DC, Keaveny TM (2017) Effect of testosterone treatment on volumetric bone density and strength in older men with low testosterone: a controlled clinical trial. JAMA Intern Med 177(4):471–479CrossRefGoogle Scholar
  32. 32.
    Orwoll ES, Lapidus J, Wang PY, Vandenput L, Hoffman A, Fink HA, Laughlin GA, Nethander M, Ljunggren Ö, Kindmark A, Lorentzon M, Karlsson MK, Mellström D, Kwok A, Khosla S, Kwok T, Ohlsson C, for the Osteoporotic Fractures in Men (MrOS) Study Research Group (2017) The limited clinical utility of testosterone, estradiol, and sex hormone binding globulin measurements in the prediction of fracture risk and bone loss in older men. J Bone Miner Res 32(3):633–640CrossRefGoogle Scholar
  33. 33.
    Verroken C, Pieters W, Beddeleem L, Goemaere S, Zmierczak HG, Shadid S, Kaufman JM, Lapauw B (2017) Cortical bone size deficit in adult patients with type 1 diabetes mellitus. J Clin Endocrinol Metab 102(8):2887–2895CrossRefGoogle Scholar
  34. 34.
    Verroken C, Zmierczak HG, Goemaere S, Kaufman JM, Lapauw B (2017) Insulin resistance is associated with smaller cortical bone size in nondiabetic men at the age of peak bone mass. J Clin Endocrinol Metab 102(6):1807–1815PubMedGoogle Scholar
  35. 35.
    Villareal DT, Aguirre L, Gurney AB, Waters DL, Sinacore DR, Colombo E, Armamento-Villareal R, Qualls C (2017) Aerobic or resistance exercise, or both, in dieting obese older adults. N Engl J Med 376(20):1943–1955CrossRefGoogle Scholar
  36. 36.
    Watson SL, Weeks BK, Weis LJ, Harding AT, Horan SA, Beck BR (2017) High-intensity resistance and impact training improves bone mineral density and physical function in postmenopausal women with osteopenia and osteoporosis: the LIFTMOR randomized controlled trial. J Bone Miner Res 33:211–220. CrossRefPubMedGoogle Scholar
  37. 37.
    Beaudart C, Biver E, Reginster JY, Rizzoli R, Rolland Y, Bautmans I, Petermans J, Gillain S, Buckinx F, Dardenne N, Bruyère O (2017) Validation of the SarQoL(R), a specific health-related quality of life questionnaire for sarcopenia. J Cachexia Sarcopenia Muscle 8(2):238–244CrossRefGoogle Scholar
  38. 38.
    Mosialou I, Shikhel S, Liu JM, Maurizi A, Luo N, He Z, Huang Y, Zong H, Friedman RA, Barasch J, Lanzano P, Deng L, Leibel RL, Rubin M, Nicholas T, Chung W, Zeltser LM, Williams KW, Pessin JE, Kousteni S (2017) MC4R-dependent suppression of appetite by bone-derived lipocalin 2. Nature 543(7645):385–390CrossRefGoogle Scholar
  39. 39.
    Jansson JO, Palsdottir V, Hägg DA, Schéle E, Dickson SL, Anesten F, Bake T, Montelius M, Bellman J, Johansson ME, Cone RD, Drucker DJ, Wu J, Aleksic B, Törnqvist AE, Sjögren K, Gustafsson JÅ, Windahl SH, Ohlsson C (2018) Body weight homeostat that regulates fat mass independently of leptin in rats and mice. Proc Natl Acad Sci U S A 115(2):427–432CrossRefGoogle Scholar
  40. 40.
    Fan Y, Hanai JI, Le PT, Bi R, Maridas D, DeMambro V et al (2017) Parathyroid hormone directs bone marrow mesenchymal cell fate. Cell Metab 25(3):661–672CrossRefGoogle Scholar
  41. 41.
    Liu P, Ji Y, Yuen T, Rendina-Ruedy E, DeMambro VE, Dhawan S et al (2017) Blocking FSH induces thermogenic adipose tissue and reduces body fat. Nature 546(7656):107–112CrossRefGoogle Scholar
  42. 42.
    Kemp JP, Morris JA, Medina-Gomez C, Forgetta V, Warrington NM, Youlten SE, Zheng J, Gregson CL, Grundberg E, Trajanoska K, Logan JG, Pollard AS, Sparkes PC, Ghirardello EJ, Allen R, Leitch VD, Butterfield NC, Komla-Ebri D, Adoum AT, Curry KF, White JK, Kussy F, Greenlaw KM, Xu C, Harvey NC, Cooper C, Adams DJ, Greenwood CMT, Maurano MT, Kaptoge S, Rivadeneira F, Tobias JH, Croucher PI, Ackert-Bicknell CL, Bassett JHD, Williams GR, Richards JB, Evans DM (2017) Identification of 153 new loci associated with heel bone mineral density and functional involvement of GPC6 in osteoporosis. Nat Genet 49(10):1468–1475CrossRefGoogle Scholar
  43. 43.
    Farr JN, Xu M, Weivoda MM, Monroe DG, Fraser DG, Onken JL, Negley BA, Sfeir JG, Ogrodnik MB, Hachfeld CM, LeBrasseur NK, Drake MT, Pignolo RJ, Pirtskhalava T, Tchkonia T, Oursler MJ, Kirkland JL, Khosla S (2017) Targeting cellular senescence prevents age-related bone loss in mice. Nat Med 23(9):1072–1079CrossRefGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2018

Authors and Affiliations

  1. 1.Centre for Metabolic Bone DiseasesUniversity Hospitals LeuvenLeuvenBelgium

Personalised recommendations